報價延遲最少15分鐘:2024/05/02 00:31 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.22 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.74/-3.44
|
|
企業價值
284.39M
|
| 資產負債 |
|
每股賬面淨值
3.93
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/02 00:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase. |